Mark Wilterding - Edwards Lifesciences VP Relations
EWL Stock | EUR 70.08 0.26 0.37% |
Insider
Mark Wilterding is VP Relations of Edwards Lifesciences
Phone | 949 250 2500 |
Web | https://www.edwards.com |
Edwards Lifesciences Management Efficiency
The company has return on total asset (ROA) of 0.1334 % which means that it generated a profit of $0.1334 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2614 %, meaning that it generated $0.2614 on every $100 dollars invested by stockholders. Edwards Lifesciences' management efficiency ratios could be used to measure how well Edwards Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | INSIDER Age | ||
Mary Moreland | Abbott Laboratories | 57 | |
Sean Lennon | Medtronic PLC | N/A | |
Vamsi Pudipeddi | Align Technology | 51 | |
Michel DVM | Siemens Healthineers AG | 62 | |
Ivan Fong | Medtronic PLC | 62 | |
Bernhard Montag | Siemens Healthineers AG | 54 | |
Carsten Bertram | Siemens Healthineers AG | N/A | |
Emory Wright | Align Technology | 53 | |
MSc MD | Medtronic PLC | N/A | |
Joseph Hogan | Align Technology | 66 | |
Jeffrey Mirviss | Boston Scientific | 57 | |
Michael Mahoney | Boston Scientific | 58 | |
Christian Klaussner | Siemens Healthineers AG | N/A | |
Julie Coletti | Align Technology | 54 | |
Mark Ploof | Medtronic PLC | N/A | |
John Sorenson | Boston Scientific | 55 | |
Catherine Jennings | Boston Scientific | N/A | |
Robert Funck | Abbott Laboratories | 62 | |
John Morici | Align Technology | 56 | |
Zelko Relic | Align Technology | 58 | |
Scott Leinenweber | Abbott Laboratories | 51 |
Management Performance
Return On Equity | 0.26 | |||
Return On Asset | 0.13 |
Edwards Lifesciences Leadership Team
Elected by the shareholders, the Edwards Lifesciences' board of directors comprises two types of representatives: Edwards Lifesciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Edwards. The board's role is to monitor Edwards Lifesciences' management team and ensure that shareholders' interests are well served. Edwards Lifesciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Edwards Lifesciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Scott Ullem, Co CFO | ||
Larry Wood, Co Replacement | ||
Mark Wilterding, VP Relations | ||
Donald Bobo, Corp Devel | ||
Todd Brinton, Co Officer | ||
Arnold Pinkston, Corp Counsel | ||
Dirksen Lehman, Co Affairs | ||
Michael Mussallem, Chairman CEO | ||
JeanLuc Lemercier, Middle Europe | ||
Christine McCauley, Co HR |
Edwards Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Edwards Lifesciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.26 | |||
Return On Asset | 0.13 | |||
Profit Margin | 0.28 % | |||
Operating Margin | 0.33 % | |||
Current Valuation | 43.48 B | |||
Shares Outstanding | 608.31 M | |||
Shares Owned By Insiders | 0.82 % | |||
Shares Owned By Institutions | 86.92 % | |||
Price To Earning | 45.19 X | |||
Price To Book | 7.49 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Edwards Stock
Edwards Lifesciences financial ratios help investors to determine whether Edwards Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Edwards with respect to the benefits of owning Edwards Lifesciences security.